scholarly journals 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

2021 ◽  
Author(s):  
Elena Gerhard‐Hartmann ◽  
Helen Goergen ◽  
Paul J. Bröckelmann ◽  
Anja Mottok ◽  
Tabea Steinmüller ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Study Group ◽  
Classical Hodgkin Lymphoma ◽  
German Hodgkin Study Group ◽  
Programmed Cell Death 1

scholarly journals Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Blood ◽  
2016 ◽  
Vol 127 (18) ◽  
pp. 2189-2192 ◽  
Author(s):  
Boris Böll ◽  
Helen Goergen ◽  
Karolin Behringer ◽  
Paul J. Bröckelmann ◽  
Felicitas Hitz ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Lung Toxicity ◽  
Study Group ◽  
German Hodgkin Study Group ◽  
Key Points

Key Points Two cycles of ABVD or AVD were equally tolerable in older early-stage favorable HL patients. Excessive toxicity including severe bleomycin-induced lung toxicity occurred in older HL patients receiving 4 cycles of ABVD.

scholarly journals Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

2017 ◽  
Vol 8 (5) ◽  
pp. 175-180 ◽  
Author(s):  
Nathan D. Gay ◽  
Craig Y. Okada ◽  
Andy I. Chen ◽  
Emma C. Scott
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Brentuximab Vedotin ◽  
Post Transplantation ◽  
Future Directions ◽  
Hematopoietic Stem ◽  
Programmed Cell Death 1 ◽  
Accelerated Approval ◽  
Immunoglobulin Gamma

Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem-cell transplantation and post-transplantation brentuximab vedotin. The purpose of this article is to review the immunophysiologic basis, clinical efficacy, and toxicity of nivolumab in the treatment of cHL. In addition, we will review ongoing clinical trials and potential future directions of checkpoint inhibition in the treatment of cHL.

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group

2018 ◽  
Vol 36 (25) ◽  
pp. 2603-2611 ◽  
Author(s):  
Stephanie Sasse ◽  
Helen Goergen ◽  
Annette Plütschow ◽  
Boris Böll ◽  
Dennis A. Eichenauer ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Risk Factor ◽  
Hodgkin Lymphoma ◽  
Early Stage ◽  
Significant Risk ◽  
Combined Modality Treatment ◽  
Study Group ◽  
German Hodgkin Study Group ◽  
Multivariable Analyses ◽  
Clinical Trial Information

Purpose The prognostic effect of isolated infradiaphragmatic involvement in Hodgkin lymphoma (HL) is controversial, and there are little data about patients treated with current therapies. Therefore, we performed a risk factor analysis to focus on isolated nodal infradiaphragmatic disease in patients treated within the German Hodgkin Study Group trials HD13 (clinical trial information: ISRCTN63474366) and HD14 (clinical trial information: ISRCTN04761296) for early-stage HL. Patients and Methods Characteristics and outcomes of patients who had infradiaphragmatic HL were compared with patients who had supradiaphragmatic disease. Progression-free survival (PFS) and overall survival (OS) were estimated according to Kaplan-Meier methods and were compared between groups using the log-rank test and Cox proportional hazards regression, which was also applied for multivariable analyses that adjusted for relevant baseline characteristics. Results Of 2,903 qualified patients, 223 (7.7%) were diagnosed with isolated nodal infradiaphragmatic disease. In general, these patients were older, had a poorer performance status, were more often male, and had the nodular sclerosis subtype less often than those with supradiaphragmatic disease. After a median follow-up time of 51 months, PFS and OS were significantly worse in patients with infradiaphragmatic disease (5-year PFS and OS, 80.1% and 91.5% v 91.2% and 97.6% in patients with supradiaphragmatic disease; each P < .001). In multivariable analyses, infradiaphragmatic HL remained a significant risk factor in terms of PFS (hazard ratio [HR], 1.5; 95% CI, 1.04 to 2.2; P = .03) and OS (HR, 2.0; 95% CI, 1.2 to 3.5; P = .01). However, inferior PFS and OS could not be observed among those patients treated with the more intensive chemotherapy (two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD] in HD13, and two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPPescalated] plus two cycles of ABVD in HD14; all patients received 30 Gy of involved-field radiotherapy). Conclusion Early-stage HL that presents with infradiaphragmatic disease only represents a distinct patient group with an inferior outcome. However, this adverse outcome can be outweighed by appropriate combined modality treatment.

scholarly journals Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment

Haematologica ◽  
2018 ◽  
Vol 104 (1) ◽  
pp. e21-e24 ◽  
Author(s):  
Stephanie Sasse ◽  
Katharina Reddemann ◽  
Arjan Diepstra ◽  
Ilske Oschlies ◽  
Antje Schnitter ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Classical Hodgkin Lymphoma ◽  
Cell Death Protein
Sign in / Sign up

Export Citation Format

Share Document